Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Nivolumab plus ipilimumab versus sunitinib bij gevorderd RCC: extended follow-up CheckMate 214
okt 2019 | Uro-oncologie